Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02279745|
Recruitment Status : Completed
First Posted : October 31, 2014
Results First Posted : December 22, 2021
Last Update Posted : December 22, 2021
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Arterial Hypertension||Drug: Ralinepag||Phase 2|
This study was an open-label extension study to determine the long-term safety and tolerability of ralinepag in subjects with WHO Group 1 PAH who completed Study APD811-003. Subjects who completed Study APD811-003 and met eligibility criteria for Study APD811-007 were enrolled. Additionally, placebo-treated subjects who discontinued study drug treatment due to clinical worsening in Study APD811-003 were permitted to enroll in Study APD811-007, upon approval of the medical monitor, provided that all end of study procedures including right heart catheterization (RHC) were performed per the study protocol. The Week 25 Visit in Study APD811-003 served as the Baseline Visit for Study APD811-007.
All subjects enrolled in Study APD811-007 received open-label treatment with ralinepag. The starting dose and titration schedule were individually determined and in accordance with the starting dose and titration schedule optimized from Study APD811-003. Adjustments in the dose and titration schedule were made according to subject tolerability.
After an individual subject completed Study APD811-003 and that subject's database was locked, subject unblinding occurred. Subjects on active treatment (ralinepag) remained on their current dose and had onsite clinical assessments performed every 3 months until the subject was discontinued from the study.
Subjects in the placebo treatment group underwent a dose titration period until a stable, maximum tolerated dose (MTD) was reached (up to 9 weeks), followed by a treatment period after the MTD was determined during which monthly onsite clinic assessments were performed for the first 3 months and then every 3 months until the subject was discontinued from the study or the study was terminated. Dose reductions could be made at any time for safety reasons. Incremental dose increases were also allowed during the Treatment Period at the discretion of the Investigator (as clinically indicated) and according to the stepwise titration scheme.
Subjects were assessed for clinical worsening during each clinic visit. If clinical worsening was confirmed, the Investigator could have opted to either continue treatment with ralinepag at the current dose, increase the dose of ralinepag, interrupt treatment, or discontinue the subject at his/her discretion.
In addition, attempts were made to contact all subjects at the time of Study APD811-007 termination to assess their vital (mortality) status. After the last subject enrolled in Study APD811-007 completed approximately 6 months of the study, a cumulative all-subject data analysis was performed for all subjects who entered the study. Subjects continued to have visits to the clinic every 3 months until the Sponsor discontinued the study. At the time of the Sponsor's decision to discontinue the study, all ongoing subjects completed an End of Study Visit. A 28-day Follow-up Visit was conducted to ensure appropriate subject safety. Subjects who remained on ralinepag were eligible to transition into the Phase 3 open-label extension study (ROR-PH-303) prior to APD811-007 study termination. For those subjects that did not enroll in Study ROR-PH-303, a 28-day Follow-up Visit was conducted to evaluate ongoing subject safety, including survival status.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||45 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label Extension Study of Ralinepag in Patients With Pulmonary Arterial Hypertension|
|Actual Study Start Date :||July 8, 2015|
|Actual Primary Completion Date :||March 29, 2021|
|Actual Study Completion Date :||March 29, 2021|
Experimental: Oral Ralinepag
Ralinepag immediate-release (IR) capsules of 10, 20, 30, 40, and 100 mcg or extended-release (XR) tablets of 50, 250, and 400 mcg for oral administration.
Other Name: APD811
- Change From Baseline in Pulmonary Vascular Resistance [ Time Frame: At 1 or 2 years after the subject enrolled into the study, pending their last RHC prior to Protocol Amendment 2. ]Pulmonary vascular resistance was collected by right heart catheterization (RHC).
- Change From Baseline in Cardiac Output [ Time Frame: At 1 or 2 years after the subject enrolled into the study, pending their last RHC prior to Protocol Amendment 2. ]Cardiac output was collected by right heart catheterization (RHC).
- Change From Baseline in Cardiac Index [ Time Frame: At 1 or 2 years after the subject enrolled into the study, pending their last RHC prior to Protocol Amendment 2. ]Cardiac index was collected by right heart catheterization (RHC).
- Change From Baseline in Mean Pulmonary Arterial Pressure [ Time Frame: At 1 or 2 years after the subject enrolled into the study, pending their last RHC prior to Protocol Amendment 2. ]Mean pulmonary arterial pressure was collected by right heart catheterization (RHC).
- Time From Randomization to the First Protocol-defined Clinical Worsening Event [ Time Frame: From Baseline to 28 days following discontinuation of study drug, up to 235 weeks. ]Clinical worsening events were defined as death, or onset of a treatment-emergent adverse event (AE) with a fatal outcome occurring ≤14 days after treatment discontinuation; hospitalization for worsening PAH, heart-lung or lung transplant, or atrial septostomy; necessity of addition (or dose change) of any prostacyclin/prostacyclin analogue, phosphodiesterase type 5 inhibitor (PDE5-I) or soluble guanylate cyclase (sGC), or endothelin receptor antagonist (ERA); and the combined occurrence of a decrease in 6-Minute Walk Distance (6MWD) by at least 20% from Baseline, confirmed on two 6-Minute Walk Tests (6MWTs) on different days; worsening in WHO/New York Heart Association (NYHA) Functional Class (FC) from Baseline; and appearance of or worsening of signs/symptoms of right heart failure that did not respond to optimized oral diuretic therapy.
- Change From Baseline in 6MWD [ Time Frame: From Baseline to discontinuation of study drug, up to 235 weeks ]6MWD was measured at Baseline (prior to starting study drug) and every 3 months thereafter including the End of Study Visit.
- Change From Baseline in WHO/NYHA FC [ Time Frame: From Baseline to 28 days following discontinuation of study drug, up to 235 weeks ]
WHO/NYHA FC was measured at Baseline (prior to starting study drug) and every 3 months thereafter including at the End of Study and 28-Day Follow-up Visits. FC recorded as I, II, III, or IV based on the following:
I: PH but without limitation of physical activity; physical activity without undue dyspnea or fatigue, chest pain or near syncope.
II: PH with slight limitation of physical activity; physical activity causes undue dyspnea or fatigue, chest pain or near syncope.
III: PH with marked limitation of physical activity; less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope.
IV: PH with inability to carry out any physical activity without symptoms. Signs of right heart failure. Dyspnea and/or fatigue at rest. Discomfort is increased by any physical activity.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02279745